Press Releases

Sign up for Email Alerts Press Release RSS

04/25/2019
Bristol-Myers Squibb Reports First Quarter Financial Results
Term:Corporate/Financial News
Language:English
04/17/2019
Bristol-Myers Squibb Company Announces Commencement of Exchange Offers and Consent Solicitations for Celgene Notes
Term:Corporate/Financial News
Language:English
04/12/2019
Bristol-Myers Squibb Shareholders Approve Celgene Acquisition
Term:Corporate/Financial News
Language:English
04/11/2019
Bristol-Myers Squibb Receives 2019 ENERGY STAR® Partner of the Year – Sustained Excellence Award
Term:Bristol-Myers
Language:English
04/02/2019
Bristol-Myers Squibb Announces Long-Term Survival Results from Pooled Analyses of Opdivo (nivolumab) in Previously-Treated Non-Small Cell Lung Cancer Patients
Term:Corporate/Financial News
Language:English
03/29/2019
Bristol-Myers Squibb Issues Statement on Celgene’s Settlement with Alvogen on Revlimid® Patent Litigation
Term:Corporate/Financial News
Language:English
03/29/2019
Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Bristol-Myers Squibb Shareholders Vote “FOR” Proposed Merger with Celgene
Term:Corporate/Financial News
Language:English
03/25/2019
Bristol-Myers Squibb Board of Directors Sends Letter to Shareholders Highlighting the Compelling Strategic and Financial Rationale of the Celgene Transaction; Company Provides Additional Investor Materials
Term:Corporate/Financial News
Language:English
03/19/2019
Bristol-Myers Squibb Files Investor Presentation Highlighting Significant Benefits of Pending Transaction with Celgene
Term:Corporate/Financial News
Language:English
03/17/2019
AUGUSTUS Demonstrates Favorable Safety Results of Eliquis® Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation Patients with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention
Term:$BMY
Language:English

Business Wire NewsHQ^sm